par Wauthoz, Nathalie 
;Rosiere, Rémi ;Amighi, Karim
Référence Expert opinion on drug delivery
Publication Publié, 2020-11-01
;Rosiere, Rémi ;Amighi, Karim Référence Expert opinion on drug delivery
Publication Publié, 2020-11-01
Article révisé par les pairs
| Résumé : | Introduction: Since 1968, inhaled chemotherapy has been evaluated and has shown promising results up to phase II but has not yet reached the market. This is due to technological and clinical challenges that require to be overcome with the aim of optimizing the efficacy and the tolerance of drug to re-open new developments in this field. Moreover, recent changes in the therapeutic standard of care for treating the patient with lung cancer also open new opportunities to combine inhaled chemotherapy with standard treatments. Areas covered: Clinical and technological concerns are highlighted from the reported clinical trials made with inhaled cytotoxic chemotherapies. This work then focuses on new pharmaceutical developments using dry powder inhalers as inhalation devices and on formulation strategies based on controlled drug release and with sustained lung retention or based on nanomedicine. Finally, new clinical strategies are described in regard to the impact of the immunotherapy on the patient's standard of care. Expert opinion: The choice of the drug, inhalation device, and formulation strategy as well as the position of inhaled chemotherapy in the patient’s clinical care are crucial factors in optimizing local tolerance and efficacy as well as in its scalability and applicability in clinical practice. |
